My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about RTIX

    ALACHUA, Fla., March 8 /PRNewswire-FirstCall/ -- Regeneration
 Technologies, Inc. (RTI) (Nasdaq:   RTIX), the Florida-based processor of
 orthopedic and other biologic implants, announced today that it has
 expanded its board of directors by one position, adding Gregory P. Rainey,
 54, president of CCI Performance Group. This addition brings the total
 number of RTI board members to six.
     As president of CCI Performance Group, Rainey consults with companies
 on strategic sales and marketing issues as well as sales force performance
 improvements.
     "With his vast expertise in business development and sales leadership
 in the orthopedics market, Greg will be a great asset to the RTI board,
 "said Brian K. Hutchison, chairman, president and CEO of RTI. "Greg has a
 24-year track record of leadership and success with major players in the
 healthcare and biotech industries. We are very pleased to have him join
 us."
     Prior to founding CCI Performance Group in 2004, Rainey served 10 years
 with Stryker Corporation, with the last four years as vice president of
 sales for Stryker's Orthopedic Division. During his tenure, Rainey doubled
 the division's sales force and grew sales from $588 million to $1.13
 billion. His team also increased the company's share in spine, trauma and
 reconstructive markets. Previously, Rainey served as senior director of
 sales for Howmedica- Osteonics and helped lead the merger of two sales
 organizations from Stryker Osteonics and Howmedica in the largest
 acquisition in the history of Stryker Corporation. Previous to Stryker,
 Rainey served as director of sales for Joint Medical Corporation, as well
 as sales positions with U.S. Surgical Corporation. Rainey earned a
 bachelor's degree in biology from Loyola University.
     About Regeneration Technologies, Inc.
     RTI processes allograft and xenograft tissue into shaped implants for
 use in orthopedic and other surgeries with a commitment to science, safety
 and innovation.
     RTI also holds the patents on BioCleanse(R), the only proven tissue
 sterilization process validated to eliminate viruses, bacteria, fungi and
 spores from tissue without impacting the structural or biomechanical
 integrity of the tissue. The company has distributed more than half a
 million allograft implants sterilized with the BioCleanse process with zero
 incidence of infection. RTI is accredited by the American Association of
 Tissue Banks and was named a 2004 Technology Pioneer by the World Economic
 Forum.
     Except for historical information, any statements made in this press
 release about the company's anticipated financial results, future
 operational results, regulatory approvals or changes to the company's
 agreements with its distributors are forward-looking statements subject to
 risks and uncertainties, such as those described in the company's public
 filings on file with the Securities and Exchange Commission. Actual results
 may differ materially from anticipated results reflected in these
 forward-looking statements. Copies of the company's SEC filings may be
 obtained by contacting the company or the SEC or by visiting RTI's web site
 at www.rtix.com or the SEC's web site at www.sec.gov.
 
 

SOURCE Regeneration Technologies, Inc.